NicOx
{{primary sources|date=June 2009}}
{{Infobox company
| name = Nicox S.A.
| logo = NicOx logo.svg
| type = Société Anonyme
| traded_as = {{Euronext|COX|FR0013018124|XPAR}}
Euronext Growth
| foundation = {{Start date|1996}}
| location_city = Sophia Antipolis
| location_country = France
| homepage = {{URL|www.nicox.com}}
}}
Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health.{{Cite web | url=https://www.bloomberg.com/quote/COX:FP | title=COX: Nicox Stock Price Quote - EN Paris - Bloomberg | website=Bloomberg News }} Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.{{Cite news|url=https://www.bloomberg.com/news/articles/2017-11-23/here-s-a-french-biotech-investors-may-not-care-about-enough|title=Here's a French Biotech Investors May Not Care About Enough|work=Bloomberg.com|access-date=2018-08-08|language=en}}{{Cite web|url=https://www.boursier.com/actions/actualites/interviews/michele-garufi-pdg-de-nicox-5146.html|title = Michele Garufi, PDG de NicOx}}
Nicox is listed on Euronext Paris{{Cite web |title=NICOX {{!}} FR0013018124 {{!}} Euronext exchange Live quotes |url=https://live.euronext.com/en/product/equities/FR0013018124-XPAR |access-date=2025-05-15 |website=live.euronext.com}} (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration (FDA) approved products.{{Cite web|url=https://seekingalpha.com/symbol/NICXF|title = Nicox S.A. (NICXF) Stock Price Today, Quote & News | Seeking Alpha}}
Pipeline
Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma.{{ClinicalTrialsGov|NCT03657797|Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension}} NCX 470 is designed to release both bimatoprost, which is marketed under the brand name LUMIGAN, and nitric oxide following instillation into the eye. Bimatoprost is a prostaglandin analog, the most widely used class of drugs for IOP lowering in patients with open angle glaucoma and ocular hypertension.{{cite journal |last1=Sambhara |first1=Deepak |last2=Aref |first2=Ahmad A. |title=Glaucoma management: relative value and place in therapy of available drug treatments |journal=Therapeutic Advances in Chronic Disease |date=2014 |volume=5 |issue=1 |pages=30–43 |doi=10.1177/2040622313511286 |pmid=24381726 |pmc=3871276 }}{{Cite web|url=https://www.healio.com/news/optometry/20120225/prostaglandin-analogs-the-gold-standard-for-glaucoma|title=Prostaglandin analogs: The "gold standard" for glaucoma}}
The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.{{ClinicalTrialsGov|NCT03926026|Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis}} Nicox generates revenue from VYZULTA(R) in glaucoma and ZERVIATE(TM), or cetirizine ophthalmic solution, in allergic conjunctivitis. It has ongoing partnerships with Bausch & Lomb, Eyevance Pharmaceuticals and Ocumension Therapeutics.{{Cite news | url=https://www.bloomberg.com/press-releases/2020-03-31/nicox-nicox-announces-zerviate-launch-by-partner-eyevance-pharmaceuticals-in-the-united-states | title=NICOX: Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States | newspaper=Bloomberg.com | date=31 March 2020 }}{{Cite news|url=https://uk.reuters.com/article/brief-nicox-updates-agreement-with-ocume/brief-nicox-updates-agreement-with-ocumension-therapeutics-on-zerviate-idUKFWN2B4063|archive-url=https://web.archive.org/web/20200611191249/https://uk.reuters.com/article/brief-nicox-updates-agreement-with-ocume/brief-nicox-updates-agreement-with-ocumension-therapeutics-on-zerviate-idUKFWN2B4063|url-status=dead|archive-date=June 11, 2020|title=BRIEF-Nicox Updates Agreement with Ocumension Therapeutics on ZERVIATE|newspaper=Reuters|date=11 March 2020}}
Agreement with Ocumension
In 2019, Nicox and Ocumension Therapeutics signed an agreement to allow Ocumension the rights to develop and commercialize Zerviate, a cetirizine ophthalmic solution, for the Chinese and South East Asian markets. The deal would see Nicox eligible for up to $17.2 million, along with tiered royalties of between 5 and 9% of the net sales. In July 2021 the deal was amended and Ocumension paid $2 million to Nicox as an advance payment of future development and regulatory milestones.{{Cite web|last=NICOX|date=2021-07-05|title=Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement|url=https://www.globenewswire.com/en/news-release/2021/07/05/2257437/0/en/Nicox-to-Receive-2-Million-from-Ocumension-Therapeutics-as-Advance-Milestone-Payment-under-ZERVIATE-Agreement.html|access-date=2021-09-19|website=GlobeNewswire News Room|language=en}}
References
{{reflist}}
External links
- [http://www.nicox.com/ Official website of NicOx]
- [https://web.archive.org/web/20160303205016/http://www.nitricoxideonline.net/ Nitric Oxide Knowledge Center - Website of NicOx]
Category:Pharmaceutical companies of France
Category:Companies based in Provence-Alpes-Côte d'Azur